Stay updated with breaking news from Nasdaq Grcl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cantor Fitzgerald reaffirmed their overweight rating on shares of Gracell Biotechnologies (NASDAQ:GRCL – Free Report) in a research note released on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $20.00 price objective on the stock. A number of other analysts also recently issued reports on GRCL. Citigroup dropped their price target on shares of Gracell […]
Gracell Biotechnologies (NASDAQ:GRCL – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Monday, August 14th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link. Gracell […]
Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Rating) – Analysts at HC Wainwright decreased their Q2 2023 earnings estimates for Gracell Biotechnologies in a research note issued on Monday, May 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.41) for the quarter, down from their prior forecast […]
Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Rating) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 391,200 shares, a decline of 9.2% from the March 31st total of 430,800 shares. Based on an average daily trading volume, of 325,100 shares, […]
Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Rating) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 430,800 shares, a growth of 14.8% from the March 15th total of 375,400 shares. Currently, 0.7% of the shares of the company are sold short. Based on […]